BRAF and melanoma: In the current landscape, superior response rates observed with BRAF/MEK inhibitors and PD-1/CTLA-4 inhibitors have resulted in these agents supplanting HD IL-2 in the treatment of melanoma patients; particularly when coupled with the attendant complexities of HD IL-2 administration.